Quality of life among patients with multiple sclerosis treated with prolonged-release fampridine 10 mg tablets for walking impairment

  • Y. L
  • M. M
  • A. L
  • et al.
Citations of this article
Mendeley users who have this article in their library.


Objectives: To evaluate the effect of prolonged-release (PR) fampridine 10 mg tablet on generic quality of life (QoL) as measured by the EQ-5D in patients with multiple sclerosis (MS) with walking impairment. Methods: The study population included 132 patients who enrolled in a 24-week randomized, double-blind, and placebo-controlled phase 2 trial (NCT01597297) of PR-fampridine 10 mg tablets or placebo twice daily in multiple sites in Europe and Canada. Patients were categorized into three groups: placebo, PR-fampridine responders (those with a mean improvement from baseline in the 12-item MS walking scale [MSWS- 12] of > 8 points over 24 weeks), and PR-fampridine nonresponders (those with worsening, no change, or < 8 points improvement in MSWS-12). Changes from baseline were calculated for the EQ-5D utility index and visual analogue scale (VAS) by visit and over the 24 weeks. Within-group and pairwise comparisons were assessed based on the least square (LS) means using analysis of covariance (ANCOVA) models adjusting for baseline EQ-5D scores. Results: The placebo patients (n= 64), responders (n= 33), and nonresponders (n= 35) were similar in baseline age, race, weight, and number of relapses in the past 1 and 2 years. The responders had higher mean baseline EQ-5D utility (0.56 vs. 0.51 and 0.52, respectively) and VAS (62.9 vs. 59.1 and 60.5, respectively) scores than the placebo patients and nonresponders. Over the 24 weeks, the EQ-5D utility score improved in the responders (mean change: 0.06, 95% CI: [0.01, 0.12]) but worsened in the placebo patients (mean change: -0.03,95% CI: [-0.07, 0.01]) and nonresponders (mean change: -0.07,95% CI: [-0.12, -0.02] ). Similar trends were observed in the VAS scores although the differences within groups were generally not statistically significant. Conclusions: PR-fampridine 10 mg tablets demonstrated significantly greater improvement in QoL among responders, despite starting from higher baseline EQ-5D scores, than the placebo or nonresponder groups.




Y., L., M., M., A., L., J., Z., & L.R., M. (2014). Quality of life among patients with multiple sclerosis treated with prolonged-release fampridine 10 mg tablets for walking impairment. Value in Health. Y. Liu, Biogen Idec, Cambridge, MA, United States: Elsevier Ltd. Retrieved from http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed12&NEWS=N&AN=71672855

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free